BofA upgraded Concentra (CON) to Buy from Neutral with a $24 price target. More than 61% of Concentra’s revenue comes from workers’ comp, where rates are set by the states and paid by employers, not states, notes the analyst. In this context, the firm views Concentra being “largely immune” to post-elections headlines and uncertainty that hospitals will face in 2025. Additionally, the outlook for the economy has slightly improved post elections, which is positive for the underlying demand, and the completion of the spin-off from Select Medical (SEM) removes a “technical overhang for the stock,” the analyst added.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CON:
- Concentra downgraded to Sell from Hold at Spin-Off Research
- Concentra announces completion of spin-off from Select Medical
- Select Medical downgraded to Hold at Benchmark after Concentra spin
- Concentra to replace Myers Industries in S&P 600 at open on 11/27
- Select Medical announces distribution ratio for special stock distribution